文献速递前列腺癌

剂量强化对比常规剂量挽救性放疗用于前列腺切除术后生化复发前列腺癌:SAKK 09/10随机3期试验

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.
PubMed 文献 · Eur Urol · 2021-06-14

SAKK 09/10随机3期试验纳入350例前列腺切除术后生化进展患者,随机接受常规剂量64 Gy或剂量强化70 Gy前列腺床挽救性放疗(无激素治疗)。中位随访6.2年,两组生化进展自由生存(FFBP)无显著差异(中位8.2年 vs 7.6年,HR 1.14,95%CI 0.82-1.60,P=0.4),6年FFBP率62% vs 61%。剂量强化组晚期2级胃肠道毒性显著增加(20% vs 7.3%,P=0.009),生活质量无差异。结论:常规剂量挽救性放疗对早期生化进展患者已足够。

要点

  • 剂量强化至70 Gy未改善生化进展自由生存,中位FFBP 7.6年 vs 8.2年(HR 1.14,P=0.4)。
  • 剂量强化组晚期2级胃肠道毒性显著更高(20% vs 7.3%,P=0.009)。
  • 两组临床PFS、至激素治疗时间、总生存及生活质量均无显著差异。

核心结论

  • 常规剂量64 Gy前列腺床挽救性放疗对前列腺切除术后早期生化进展患者已足够。

研究设计与样本

  • SAKK 09/10为随机、多中心、3期试验,2011年2月至2014年4月招募350例前列腺切除术后生化进展男性,随机分配至64 Gy组(n=175)或70 Gy组(n=175)。

主要发现

  • 中位随访6.2年,中位FFBP在64 Gy组为8.2年、70 Gy组为7.6年(log-rank P=0.4),HR 1.14(95%CI 0.82-1.60)。
  • 6年FFBP率分别为62%和61%。
  • 临床PFS、至激素治疗时间及OS均无显著差异。
  • 晚期2级和3级泌尿生殖毒性在64 Gy组分别为35例(21%)和13例(7.9%),70 Gy组分别为46例(26%)和7例(4%)(P=0.8)。
  • 晚期2级和3级胃肠道毒性在64 Gy组分别为12例(7.3%)和7例(4.2%),70 Gy组分别为35例(20%)和4例(2.3%)(P=0.009)。

关键数值与推荐

  • 随机时中位PSA为0.3 ng/ml。
  • 常规剂量组64 Gy,剂量强化组70 Gy,均针对前列腺床且不联合激素治疗。
  • 主要终点为生化进展自由生存(FFBP),次要终点包括临床PFS、至激素治疗时间、OS、急性和晚期毒性(CTCAE v4.0)及生活质量。

临床怎么用

  • 对前列腺切除术后早期生化进展患者,可选择常规剂量64 Gy前列腺床挽救性放疗,避免剂量强化带来的胃肠道毒性增加。

局限性

  • 原文未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage radiotherapy (SRT) is utilized for biochemical progression of prostate cancer after radical prostatectomy (RP). OBJECTIVE: To report the outcomes of the SAKK 09/10 trial comparing conventional and dose-intensified SRT. DESIGN, SETTING, AND PARTICIPANTS: SAKK 09/10 was a randomized, multicenter, phase 3 trial that recruited men with biochemical progression after RP. INTERVENTION: Patients were randomly assigned to conventional-dose (64 Gy) or dose-intensified SRT (70 Gy) to the prostate bed without hormonal therapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was freedom from biochemical progression (FFBP). Secondary endpoints included clinical progression-free survival (PFS), time to hormonal treatment, overall survival (OS), acute and late toxicity (Common Terminology Criteria for Adverse Events v4.0), and quality of life (QoL). RESULTS AND LIMITATIONS: Between February 2011 and April 2014, 350 patients were randomly assigned to 64 Gy (n = 175) or 70 Gy (n = 175). Median prostate-specific antigen at randomization was 0.3 ng/ml. After median follow-up of 6.2 yr, the median FFBP was 8.2 yr in the 64 Gy arm and 7.6 in the 70 Gy arm (log-rank p = 0.4), with a hazard ratio of 1.14 (95% confidence interval 0.82-1.60). The 6-year FFBP rates were 62% and 61%, respectively. No significant differences in clinical PFS, time to hormonal treatment, or OS were observed. Late grade 2 and 3 genitourinary toxicity was observed in 35 (21%) and 13 (7.9%) patients in the 64 Gy arm, and 46 (26%) and seven (4%) in the 70 Gy arm, respectively (p = 0.8). Late grade 2 and 3 gastrointestinal toxicity was observed in 12 (7.3%) and seven patients (4.2%) in the 64 Gy arm, and 35 (20%) and four (2.3%) in the 70 Gy arm, respectively (p = 0.009). There were no significant differences in QoL. CONCLUSIONS: Conventional-dose SRT to the prostate bed is sufficient in patients with early biochemical progression of prostate cancer after RP. PATIENT SUMMARY: The optimal radiation therapy dose for patients who have increased tumor markers after surgery for prostate cancer is unclear. We found that administering a higher dose only increased the gastrointestinal side effects without providing any benefits to the patient. This clinical trial is registered on ClinicalTrials.gov as NCT01272050.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ghadjar P, Hayoz S, Bernhard J, et al. Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. Eur Urol. 2021. PMID: 34140144. doi:10.1016/j.eururo.2021.05.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。